

**REVENUE MEMORANDUM CIRCULAR NO. 93-2024** issued on August 28, 2024 publishes the full text of the June 20, 2024 letter from the Food and Drug Administration of the Department of Health endorsing updates to the List of VAT-exempt products under Republic Act (RA) No. 10963 (TRAIN Law) and RA No. 11534 (CREATE Act) which now includes certain medicines for cancer, high cholesterol, hypertension, and mental illness, and deletes medicines for hypertension.

As clarified under Q&A No. 1 of Revenue Memorandum Circular No. 99-2021, the effectivity of the VAT exemption of the covered medicines and medical devices under the CREATE Act shall be on the date of publication by the FDA of the updates to the said list.